Please assess the completion status of the following clinical trial:

Trial Title: Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hormone-sensitive prostate cancer~* Non-metastatic disease, as evidenced by negative bone scan or computed tomography of the abdomen and pelvis~* ECOG performance status ≤ 1~* Histologically documented prostate cancer~* Prior primary therapy for prostate cancer~* Rising PSA with a PSADT of ≤ 12 months~* Testosterone ≥ 200 ng/dL ≤ 28 days of registration~* Adequate hematologic, renal, and liver function~* Must live in a permanent residence within a comfortable driving distance (round-trip within one day) to the clinical research site~Exclusion Criteria:~* Requires systemic ongoing immunosuppressive therapy~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to sipuleucel-T or GM-CSF~* Prior sipuleucel-T therapy~* Prior ADT therapy ≤ 6 months prior to registration or ≥ 6 months duration in total~* If subject has a history of any other stage III/IV malignancy, the subject must be disease free and off any malignancy-related treatment for at least 10 years. If the subject has a history of any stage I-II malignancy, the subject must be disease free and off any malignancy-related treatment for at least 5 years.~* Prior experimental immunotherapy or on an experimental clinical trial within 1 year~* Received denosumab or XRT ≤ 6 months prior to registration~* Received chemotherapy or GM-CSF ≤ 90 days prior to registration~* Received any of the following medications or interventions ≤ 28 days prior to registration~  * major surgery requiring general anesthesia~ * systemic immunosuppressive therapy~ * other prescription treatment for prostate cancer~* Active infection within 1 week of registration~* Likely to receive XRT or surgery for prostate cancer during the study period~* Any medical intervention, any other condition, or any circumstances that could compromise the study.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: Sipuleucel-T followed by ADT (Type: EXPERIMENTAL): Arm 1: Subjects received one infusion of sipuleucel-T every two weeks for a total of three infusions. Two weeks after the third sipuleucel-T infusion, subjects started ADT with 45 mg leuprolide acetate depot injection (Eligard® 45 mg). An additional leuprolide acetate injection was administered at 6 months after the first injection for a total of 2 injections and 12 months of ADT.
- Arm 2: ADT followed by sipuleucel-T (Type: EXPERIMENTAL): Arm 2: Subjects started ADT with 45 mg leuprolide acetate depot injection (Eligard® 45 mg) 12 weeks before infusion 1 of sipuleucel-T. An additional leuprolide acetate injection was administered at 6 months after the first injection for a total of 2 injections and 12 months of ADT. Twelve weeks after the initial leuprolide 45 mg depot injection, subjects began one infusion of sipuleucel-T every two weeks for a total of three infusions.

Based on this trial design, predict the completion outcome and termination type (if applicable).